Clinical and cellular outcome in recipients at term (n=179 recipients)
| Group 1 (n=143) | Group 2 (n=36) | p Value | |
|---|---|---|---|
| *Measurements performed on 154 grafts clear at term. | |||
| BCVA = Best corrected visual acuity. | |||
| Global graft survival (%) | 87.4 | 80.6 | 0.197 |
| LogMAR BCVA (mean (Snellen) (SD)) | |||
| Term of study | 0.64 (20/100)(0.65) | 0.87 (20/160)(0.75) | 0.069 |
| During follow up | 0.51 (20/63)(0.53) | 0.59 (20/80)(0.52) | 0.422 |
| Term astigmatism (dioptres, mean (SD)) | 3.7 (2.0) | 3.01 (2.0) | 0.085 |
| Rejection % (n) | 16 (23) | 33 (12) | 0.020 |
| Hypertony % (n) | 13 (19) | 14 (5) | 0.924 |
| Term ECD (cells/mm2, mean (SD), min − max)* | 1183 (463)(370 − 2677) | 1078 (549)(239 − 1989) | 0.352 |
| Surface variation coefficent (%, mean (SD))* | 28.2 (7.0) | 28.7 (7.4) | 0.706 |
| Hexagonality coefficient (%, mean (SD))* | 56.2 (17.4) | 53.2 (18.5) | 0.410 |
| Follow up (month, mean (SD), range) | 25.8 (12.6)(0–50) | 22.9 (12.7)(2–47) | 0.223 |